Active Filter(s):
Details:
Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lead Product(s): Plerixafor
Therapeutic Area: Oncology Product Name: Mozobil-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
Diltiazem hydrochloride inhibits the inflow of calcium ions into the cardiac muscle during depolarization. Reduced intracellular calcium concentrations increase smooth muscle relaxation, resulting in arterial vasodilation and decreased blood pressure.
Lead Product(s): Diltiazem Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diltiazem Hydrochloride-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Lenalidomide (revlimid's-generic) activates NK cells, which leads to heightened immune surveillance the ability of the immune system to both identify and eliminate tumor cells. Lenalidomide has tumoricidal effects on multiple myeloma.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Revlimid-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Hydralazine is a vasodilator which alters cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.
Lead Product(s): Hydralazine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Hydralazine Hydrochloride-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Vfend-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Azacitidine is a pyrimidine nucleoside analog of cytidine. It is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.
Lead Product(s): Azacitidine
Therapeutic Area: Oncology Product Name: Vidaza-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023